How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

34,964 results for

Plaque

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Non obstructive high-risk plaque but not calcified by coronary CTA, and the G-score predict ischemia. (PubMed)

Non obstructive high-risk plaque but not calcified by coronary CTA, and the G-score predict ischemia. The association of plaque morphology with ischemia in non-obstructive lesions has not been fully eludicated: Calcium density and high-risk plaque features have not been explored.to assess whether high-risk plaque or calcified, and global mixed including non-calcified plaque burden (G-score) by coronary CTA predict ischemia in non-obstructive lesions using non-invasive fractional flow reserve (...) (FFRCT).In 106 patients with low-to-intermediate pre-test probability referred to coronary 128-slice dual source CTA, lesion-based and distal FFRCT were computated. The 4 high-risk-plaque criteria: Low-attenuation-plaque, Napkin Ring Sign, positive remodelling and spotty calcification were recorded. Plaque density (HU) and stenosis (MLA,MLD,%area,%diameter stenosis) were quantified. Plaque composition was classified as type 1-4:1 = calcified, 2 = mixed (calcified > non-calcified), 3 = mixed (non

2019 Journal of cardiovascular computed tomography

162. Extreme Levels of Air Pollution Associated with Changes in Biomarkers of Atherosclerotic Plaque Vulnerability and Thrombogenicity in Healthy Adults: The Beijing AIRCHD Study. (PubMed)

Extreme Levels of Air Pollution Associated with Changes in Biomarkers of Atherosclerotic Plaque Vulnerability and Thrombogenicity in Healthy Adults: The Beijing AIRCHD Study. The pathophysiologic mechanisms of air pollution-associated exacerbation of cardiovascular events remain incompletely understood.To assess whether ambient air pollution can be a trigger of the vulnerable plaque and heightened thrombogenicity through systemic inflammatory pathways.In Beijing AIRCHD study (Air Pollution (...) and Cardiovascular Dysfunctions in Healthy Adults Living in Beijing), 73 healthy adults (mean±SD, 23.3±5.4 years) were followed up in 2014 to 2016. We estimated associations between air pollutants and biomarkers relevant to atherosclerotic plaque vulnerability, thrombogenicity, and inflammation using linear mixed-effects models and elucidated the biological pathways involved using mediation analyses. Receiver operating characteristic analyses were conducted to assess the ability of each biomarker to predict

Full Text available with Trip Pro

2019 Circulation Research

163. Mycosis fungoides presenting as vulvar plaques. (PubMed)

Mycosis fungoides presenting as vulvar plaques. 30653269 2019 02 27 1468-3083 2019 Jan 17 Journal of the European Academy of Dermatology and Venereology : JEADV J Eur Acad Dermatol Venereol Mycosis fungoides presenting as vulvar plaques. 10.1111/jdv.15429 El Alami J J Department of Dermatology, INSERM U976, Saint-Louis Hospital, APHP, Paris Diderot University, 49100 Angers, Paris, France. Le Corre Y Y Department of Dermatology, University Hospital of Angers, UBL University, Angers, 75010 Paris

2019 Journal of the European Academy of Dermatology and Venereology

164. The challenge of asymptomatic coronary artery disease in aircrew; detecting plaque before the accident. (PubMed)

The challenge of asymptomatic coronary artery disease in aircrew; detecting plaque before the accident. Coronary events remain a major cause of sudden incapacitation, including death, in both the general population and among aviation personnel, and are an ongoing threat to flight safety and operations. The presentation is often unheralded, especially in younger adults, and is often due to rupture of a previously non-obstructive coronary atheromatous plaque. The challenge for aeromedical

Full Text available with Trip Pro

2019 Heart

165. Recurrent fevers, progressive lipodystrophy, and annular plaques in a child. (PubMed)

Recurrent fevers, progressive lipodystrophy, and annular plaques in a child. KEY TEACHING POINTS.Published by Elsevier Inc.

2019 Journal of the American Academy of Dermatology

166. Efficacy of adjunctive anti-plaque chemical agents in managing gingivitis: a systematic review and network meta-analyses. (PubMed)

Efficacy of adjunctive anti-plaque chemical agents in managing gingivitis: a systematic review and network meta-analyses. The aim of this network meta-analysis (NMA) was to compare the efficacy of different oral hygiene products for chemical biofilm control, in 6-month home-use, randomised clinical trials (RCTs), in terms of changes in gingival index (GI).Six-month RCTs assessing GI were identified and screened for inclusion. Relevant information was extracted, quality and potential risk

2019 Journal of Clinical Periodontology

167. Ruthenium-106 versus iodine-125 plaque brachytherapy of 571 choroidal melanomas with a thickness of ≥5.5 mm. (PubMed)

Ruthenium-106 versus iodine-125 plaque brachytherapy of 571 choroidal melanomas with a thickness of ≥5.5 mm. Episcleral brachytherapy is the most common eye-preserving treatment for medium-sized choroidal melanomas. γ-emitting iodine-125 (125I) and β-emitting ruthenium-106 (106Ru) are widely used. The latter is however generally reserved for thinner tumours (<6 mm). In this study, we compare ocular and patient survival in thicker tumours treated with the respective radioisotope.All patients (...) with ≥5.5 mm thick choroidal melanomas who were treated with plaque brachytherapy at a single institution between 1 November 1979 and 31 December 2015 were included (n=571). Size-controlled Cox regression HRs for postbrachytherapy enucleation, repeated brachytherapy and melanoma-related mortality were calculated, as well as Kaplan-Meier disease-specific survival and relative 10-year survival in matched subgroups.317 patients were treated with 106Ru and 254 with 125I. The rate of repeated brachytherapy

2019 British Journal of Ophthalmology

168. Imaging biomarkers of vulnerable carotid plaques for stroke risk prediction and their potential clinical implications. (PubMed)

Imaging biomarkers of vulnerable carotid plaques for stroke risk prediction and their potential clinical implications. Stroke represents a massive public health problem. Carotid atherosclerosis plays a fundamental part in the occurence of ischaemic stroke. European and US guidelines for prevention of stroke in patients with carotid plaques are based on quantification of the percentage reduction in luminal diameter due to the atherosclerotic process to select the best therapeutic approach (...) . However, better strategies for prevention of stroke are needed because some subtypes of carotid plaques (eg, vulnerable plaques) can predict the occurrence of stroke independent of the degree of stenosis. Advances in imaging techniques have enabled routine characterisation and detection of the features of carotid plaque vulnerability. Intraplaque haemorrhage is accepted by neurologists and radiologists as one of the features of vulnerable plaques, but other characteristics-eg, plaque volume

2019 Lancet Neurology

169. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate to severe plaque-type psoriasis: Results from extension phase of the SUPREME study. (PubMed)

Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate to severe plaque-type psoriasis: Results from extension phase of the SUPREME study. Recent studies have shown that biological drugs approved for treating psoriasis and psoriatic arthritis are not effective in all patients, and that variations in the genome have been associated with different clinical responses or side effects. HLA-Cw6 gene is associated with more severe and early-onset psoriasis. Recent (...) reports have shown that HLA-Cw6 status predicts efficacy of some biologic treatments in psoriasis patients. The Phase 3b SUPREME study (NCT02394561) demonstrated the efficacy of secukinumab in patients with moderate-to-severe plaque-type psoriasis, irrespective of HLA-Cw6 status at week 24. This article is protected by copyright. All rights reserved.This article is protected by copyright. All rights reserved.

2019 British Journal of Dermatology

170. Efficacy of secukinumab without the initial weekly loading dose in patients with chronic plaque psoriasis. (PubMed)

Efficacy of secukinumab without the initial weekly loading dose in patients with chronic plaque psoriasis. Secukinumab is administered at the labelled dose of 300 mg at weeks 0, 1, 2, 3, 4 (loading dose) and every 4 weeks thereafter.To investigate the efficacy of secukinumab administered without the initial loading dose in patients with psoriasis.a retrospective, observational study including adult patients with psoriasis (n=156) treated with secukinumab 300 mg administered either according

2019 British Journal of Dermatology

171. Sustained Long-Term Efficacy and Safety of Adalimumab in Pediatric Patients with Severe Chronic Plaque Psoriasis from a Randomised, Double-Blind, Phase 3 Study. (PubMed)

Sustained Long-Term Efficacy and Safety of Adalimumab in Pediatric Patients with Severe Chronic Plaque Psoriasis from a Randomised, Double-Blind, Phase 3 Study. Adalimumab (Humira® , AbbVie Inc, USA) is EMA approved for children ages ≥4 years with severe plaque-psoriasis.Evaluate long-term efficacy and safety of adalimumab in children with severe plaque psoriasis.Results are from the 52-week long-term extension (LTE) of the randomized, double-blind, double-dummy, phase-3 trial, in children (...) with severe plaque psoriasis (results from prior periods are published). Patients aged ≥4-<18 years were randomised 1:1:1 to adalimumab (ADA) 0·8mg/kg (40mg maximum) or 0·4mg/kg (20mg maximum) every-other-week or to methotrexate (MTX) 0·1-0·4mg/kg (25mg maximum) weekly. The 16-week Initial Treatment (IT) period was followed by a 36-week Withdrawal period and a 16-week Re-treatment period. Patients could enter the LTE at pre-specified time points to receive ADA 0·8mg/kg (blinded or open-label), ADA 0·4mg

2019 British Journal of Dermatology

172. Development of clinical diagnostic criteria for plaque psoriasis in children: An eDelphi consensus study with the International Psoriasis Council. (PubMed)

Development of clinical diagnostic criteria for plaque psoriasis in children: An eDelphi consensus study with the International Psoriasis Council. Psoriasis in children can be a challenging diagnosis: the clinical presentation is often more subtle, may occur in covered sites and can be an unexpected diagnosis as psoriasis if often thought to occur at older ages. Poor recognition and delayed diagnosis of psoriasis in children can lead to inadequate treatment and lack of monitoring

2019 British Journal of Dermatology

173. Vulnerable plaque and vulnerable blood: Two critical factors for spontaneous atherothrombosis in mouse models. (PubMed)

Vulnerable plaque and vulnerable blood: Two critical factors for spontaneous atherothrombosis in mouse models. Atherothrombotic events such as myocardial infarction and ischemic stroke are a major cause of morbidity and mortality worldwide. Understanding the molecular and cellular mechanisms of atherosclerotic plaque destabilization or erosion, and developing new therapeutics to prevent acute cardiovascular events is important for vascular biology research and clinical cardiovascular medicine (...) . However, basic research on plaque destabilization, rupture and erosion is hampered by the lack of appropriate animal models of atherothrombosis. Unprovoked atherothrombosis is very scarce in commonly used mouse models for atherosclerosis, the low-density lipoprotein receptor knockout and apolipoprotein E knockout mice. Therefore, specific interventions are required to induce atherothrombosis in these models. Two strategies can be employed to induce atherothrombosis: 1) plaque destabilization and 2

2019 Atherosclerosis

174. Large aortic arch plaques correlate with CHADS<sub>2</sub> and CHA<sub>2</sub>DS<sub>2</sub>-VASc scores in cryptogenic stroke. (PubMed)

Large aortic arch plaques correlate with CHADS2 and CHA2DS2-VASc scores in cryptogenic stroke. Current trends have suggested covert atrial fibrillation as a mechanism of cryptogenic stroke. However, etiological heterogeneity regarding the underlying embolic sources remains a critical issue in cryptogenic stroke.CHALLENGE ESUS/CS (Mechanisms of Embolic Stroke Clarified by Transesophageal Echocardiography for Embolic Stroke of Undetermined Source/Cryptogenic (...) was registered at http://www.umin.ac.jp/ctr/(UMIN000032957).The study comprised 677 patients (age, 68.7 ± 12.8 years; 455 males; median National Institutes of Health Stroke Scale score, 2) with cryptogenic stroke. On multiple logistic regression analysis, large aortic arch plaque ≥4 mm (odds ratio [OR], 2.25; 95% confidence interval [CI], 1.51-3.36; p < 0.001), with ulcerative or mobile components (OR, 2.37; 95%CI, 1.38-4.06; p = 0.002), was associated with CHADS2 score ≥2. Large aortic arch plaque ≥4 mm

2019 Atherosclerosis

175. Apixaban versus warfarin in evaluation of progression of atherosclerotic and calcified plaques (prospective randomized trial). (PubMed)

Apixaban versus warfarin in evaluation of progression of atherosclerotic and calcified plaques (prospective randomized trial). Warfarin has been showed to increase vascular calcification. Apixaban, a direct factor Xa inhibitor, has no interaction with vitamin K and its effect on coronary plaques is unknown. We randomized and compared warfarin and apixaban on progression of coronary atherosclerotic plaques measured by coronary computed tomographic angiography in 66 subjects with non-valvular (...) atrial fibrillation over the period of one-year follow up. There was significant higher total, calcified and low attenuation plaque volume in the group randomized to warfarin as compared to apixaban (all P < .05). Greater volume of total (β2 = 28.54; P = .03), low attenuation plaque (β2 = 3.58; P = .02) and calcified (β2 = 14.10; P = .005) plaque progression was observed in the VKA_group.Copyright © 2019 Elsevier Inc. All rights reserved.

2019 American Heart Journal

176. Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis. (PubMed)

Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis. Biologics targeting interleukin-17 are increasingly being used for treatment of moderate-to-severe psoriasis, but data on drug survival for these therapies remain scarce.To investigate the drug survival of secukinumab and ixekizumab in a nationwide cohort of patients with psoriasis in Denmark.Using Dermbio, we examined Danish patients receiving treatment with secukinumab or ixekizumab according to the standard

2019 Journal of American Academy of Dermatology

177. Poikilodermatous plaque-like hemangioma: case series of a newly defined entity. (PubMed)

Poikilodermatous plaque-like hemangioma: case series of a newly defined entity. We present a distinctive type of acquired vascular proliferation, for which we propose the name of poikilodermatous plaque-like hemangioma (PPH).The aim of the study is to summarise the clinical and histopathological features in a case series of PPH.Sixteen cases were identified from the routine clinical and referral practice of the authors. Clinical characteristics including demographic details and clinical (...) morphology were collated. The salient histopathological features including immunohistochemistry were summarised.The lesions were usually solitary erythematous to violaceous poikilodermatous plaques on the lower extremities and pelvic girdle, with an indolent clinical course. Mean age was 72 (range 58-80) years, with a male predominance. Histology comprised a distinctive band-like proliferation of vascular channels suggestive of post-capillary venules within the superficial dermis with a background

2019 Journal of American Academy of Dermatology

178. Etanercept biosimilar SB4 in the treatment of plaque-type psoriasis and psoriatic arthritis: a single-center, observational, retrospective, real-life study. (PubMed)

Etanercept biosimilar SB4 in the treatment of plaque-type psoriasis and psoriatic arthritis: a single-center, observational, retrospective, real-life study. The approval of the etanercept biosimilar SB4 (Brenzys, Benepali; Samsung Bioepis Co., Ltd.) for psoriasis and psoriatic arthritis (PsA) was automatically obtained on the basis of the demonstration of quality, biological activity, efficacy, safety, and immunogenicity similarity to the reference etanercept in the treatment of rheumatoid (...) arthritis (1, 2). Being the development of biosimilars a significant opportunity to decrease medical care cost and increase treatment options (3), extrapolation of clinical data from other indications determined an intense scientific debate on the interchangeability between originator and biosimilar in real-life, and recently reports on efficacy and safety of the biosimilar SB4 in plaque-type psoriasis have been published (4, 5). The aim of our observational, retrospective, single-center, study

2019 British Journal of Dermatology

179. Evaluation of the effect of a toothpaste containing Pudilan extract on inhibiting plaques and reducing chronic gingivitis: A randomized, double-blinded, parallel controlled clinical trial. (PubMed)

Evaluation of the effect of a toothpaste containing Pudilan extract on inhibiting plaques and reducing chronic gingivitis: A randomized, double-blinded, parallel controlled clinical trial. Pudilan is a famous traditional Chinese medicine compound which contains several Chinese herbal ingredients, is wildly used to treat a variety of inflammatory diseases in China. Recently, it was reported that Pudilan extract had been used in the oral field, especially in the treat of minor oral ulcers for its (...) anti-inflammatory, pain relieving, antibacterial, clearing heat, and detoxifying effects.To evaluate the effectiveness and safety of Pudilan extract-containing toothpaste in controlling plaques and reducing chronic gingivitis.A total of 120 patients with chronic gingivitis were randomized into an experiment group and a control group (n = 60 patients per group) based on a double-blinded method. Patients in the experiment group used a Pudilan extract-containing toothpaste, whereas patients

2019 Journal of Ethnopharmacology

180. Automated detection of superficial macrophages in atherosclerotic plaques using autofluorescence lifetime imaging. (PubMed)

Automated detection of superficial macrophages in atherosclerotic plaques using autofluorescence lifetime imaging. Macrophages play an important role in the development and destabilization of advanced atherosclerotic plaques. Hence, the clinical imaging of macrophage content in advanced plaques could potentially aid in identifying patients most at risk of future clinical events. The lifetime of the autofluorescence emission from atherosclerotic plaques has been correlated with lipids (...) and macrophage accumulation in ex vivo human coronary arteries, suggesting the potential of intravascular endogenous fluorescence or autofluorescence lifetime imaging (FLIM) for macrophage imaging. The aim of this study was to quantify the accuracy of the coronary intima autofluorescence lifetime to detect superficial macrophage accumulation in atherosclerotic plaques.Endogenous FLIM imaging was performed on 80 fresh postmortem coronary segments from 23 subjects. The plaque autofluorescence lifetime

2019 Atherosclerosis

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>